KR100593981B1 - Ｉｆｎａｒ2/ｉｆｎ 복합체 - Google Patents

Ｉｆｎａｒ2/ｉｆｎ 복합체 Download PDF

Info

Publication number
KR100593981B1
KR100593981B1 KR1020007006160A KR20007006160A KR100593981B1 KR 100593981 B1 KR100593981 B1 KR 100593981B1 KR 1020007006160 A KR1020007006160 A KR 1020007006160A KR 20007006160 A KR20007006160 A KR 20007006160A KR 100593981 B1 KR100593981 B1 KR 100593981B1
Authority
KR
South Korea
Prior art keywords
ifn
ifnβ
complex
ifnar2
ifnar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007006160A
Other languages
English (en)
Korean (ko)
Other versions
KR20010032836A (ko
Inventor
마크 테퍼
마크 추닝헴
데이비드 쉐리스
나빌 엘타야르
쉰 멕케나
Original Assignee
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. filed Critical 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.
Publication of KR20010032836A publication Critical patent/KR20010032836A/ko
Application granted granted Critical
Publication of KR100593981B1 publication Critical patent/KR100593981B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020007006160A 1997-12-19 1998-12-18 Ｉｆｎａｒ2/ｉｆｎ 복합체 Expired - Fee Related KR100593981B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
US60/068,295 1997-12-19
PCT/US1998/026926 WO1999032141A1 (en) 1997-12-19 1998-12-18 Ifnar2/ifn complex

Publications (2)

Publication Number Publication Date
KR20010032836A KR20010032836A (ko) 2001-04-25
KR100593981B1 true KR100593981B1 (ko) 2006-06-30

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007006160A Expired - Fee Related KR100593981B1 (ko) 1997-12-19 1998-12-18 Ｉｆｎａｒ2/ｉｆｎ 복합체

Country Status (27)

Country Link
US (1) US6372207B1 (enExample)
EP (1) EP1037658B1 (enExample)
JP (1) JP4601163B2 (enExample)
KR (1) KR100593981B1 (enExample)
CN (1) CN1241638C (enExample)
AR (1) AR020315A1 (enExample)
AT (1) ATE218362T1 (enExample)
AU (1) AU755078B2 (enExample)
BG (1) BG64920B1 (enExample)
BR (1) BR9813753A (enExample)
CA (1) CA2311648C (enExample)
DE (1) DE69805844T2 (enExample)
DK (1) DK1037658T3 (enExample)
EA (1) EA003635B1 (enExample)
EE (1) EE200000355A (enExample)
ES (1) ES2174530T3 (enExample)
HU (1) HUP0100456A3 (enExample)
IL (2) IL136855A0 (enExample)
NO (1) NO20002691L (enExample)
NZ (1) NZ504771A (enExample)
PL (1) PL197568B1 (enExample)
PT (1) PT1037658E (enExample)
SK (1) SK9222000A3 (enExample)
TR (1) TR200001961T2 (enExample)
UA (1) UA74132C2 (enExample)
WO (1) WO1999032141A1 (enExample)
ZA (1) ZA9811634B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
PL1666496T3 (pl) * 2003-08-25 2014-08-29 Toray Industries Kompozyt interferonu beta
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
AU2007351813B2 (en) * 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
WO2010117848A1 (en) 2009-03-31 2010-10-14 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
EP2970461A4 (en) * 2013-03-15 2016-11-23 Janssen Biotech Inc INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
KR20200015742A (ko) * 2017-06-20 2020-02-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 인터페론 전구약물
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
US6372207B1 (en) 2002-04-16
EP1037658B1 (en) 2002-06-05
JP2001526242A (ja) 2001-12-18
AR020315A1 (es) 2002-05-08
EA003635B1 (ru) 2003-08-28
WO1999032141A1 (en) 1999-07-01
BG64920B1 (bg) 2006-09-29
AU755078B2 (en) 2002-12-05
EP1037658A1 (en) 2000-09-27
HUP0100456A3 (en) 2003-09-29
NO20002691L (no) 2000-08-18
BG104539A (en) 2001-04-30
CA2311648A1 (en) 1999-07-01
DK1037658T3 (da) 2002-09-30
HUP0100456A1 (hu) 2001-06-28
CN1241638C (zh) 2006-02-15
DE69805844T2 (de) 2002-10-24
EE200000355A (et) 2001-10-15
ES2174530T3 (es) 2002-11-01
AU1926999A (en) 1999-07-12
KR20010032836A (ko) 2001-04-25
NZ504771A (en) 2002-09-27
ZA9811634B (en) 1999-06-22
PL341423A1 (en) 2001-04-09
CA2311648C (en) 2010-11-16
PT1037658E (pt) 2002-10-31
ATE218362T1 (de) 2002-06-15
DE69805844D1 (de) 2002-07-11
SK9222000A3 (en) 2001-01-18
UA74132C2 (uk) 2005-11-15
IL136855A (en) 2007-07-24
HK1032914A1 (en) 2001-08-10
EA200000685A1 (ru) 2000-12-25
PL197568B1 (pl) 2008-04-30
IL136855A0 (en) 2001-06-14
TR200001961T2 (tr) 2000-11-21
BR9813753A (pt) 2000-10-10
JP4601163B2 (ja) 2010-12-22
CN1282255A (zh) 2001-01-31
NO20002691D0 (no) 2000-05-25

Similar Documents

Publication Publication Date Title
KR100593981B1 (ko) Ｉｆｎａｒ2/ｉｆｎ 복합체
US7186805B2 (en) IL-21 antagonists
CN101115769A (zh) 干扰素-α多肽和偶联物
US20100239530A1 (en) Ifnar2 mutants, their production and use
JP2005518183A (ja) インターフェロンガンマポリペプチド変異体
US5684129A (en) Interferon receptor binding peptides
KR100688051B1 (ko) 각질세포-유래된 인터페론
MXPA00005886A (en) Ifnar2/ifn complex
CZ20002287A3 (cs) Komplex IFNAR2/IFN
AU2002366976B2 (en) IFNAR2 mutants, their production and use
AU2007202312A1 (en) IFNAR2 mutants, their production and use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090621

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090621